Novavax, Inc. (NASDAQ:NVAX) Stock Position Lifted by Vontobel Holding Ltd.

Vontobel Holding Ltd. boosted its holdings in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 110.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 498,532 shares of the biopharmaceutical company's stock after buying an additional 261,464 shares during the period. Vontobel Holding Ltd. owned approximately 0.36% of Novavax worth $6,296,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Shah Capital Management increased its position in shares of Novavax by 19.0% in the second quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company's stock worth $122,322,000 after acquiring an additional 1,544,263 shares in the last quarter. Farallon Capital Management LLC acquired a new stake in Novavax in the 1st quarter valued at $5,406,000. Renaissance Technologies LLC acquired a new stake in Novavax in the 2nd quarter valued at $14,055,000. SG Americas Securities LLC raised its position in Novavax by 940.7% in the third quarter. SG Americas Securities LLC now owns 1,154,276 shares of the biopharmaceutical company's stock valued at $14,579,000 after purchasing an additional 1,043,363 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Novavax during the second quarter worth about $4,592,000. 53.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on NVAX. Jefferies Financial Group lowered their target price on Novavax from $31.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday. B. Riley reaffirmed a "buy" rating and issued a $26.00 price objective (up previously from $23.00) on shares of Novavax in a research report on Thursday, October 10th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Novavax from $8.00 to $9.00 and gave the stock an "underweight" rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $17.83.

Novavax Trading Down 1.6 %

NVAX stock traded down $0.17 during midday trading on Friday, hitting $10.18. 7,025,702 shares of the company's stock were exchanged, compared to its average volume of 10,200,062. The firm has a 50 day moving average price of $12.48 and a 200-day moving average price of $11.66. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $23.86. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -3.21 and a beta of 2.04.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.82 by ($0.83). The company had revenue of $415.50 million for the quarter, compared to analyst estimates of $458.57 million. During the same period in the previous year, the business posted $0.58 EPS. The company's revenue was down 2.1% on a year-over-year basis. On average, sell-side analysts forecast that Novavax, Inc. will post -0.97 EPS for the current fiscal year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.